Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Channing Capital Management LLC

Channing Capital Management LLC lowered its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 1.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 49,931 shares of the medical research company’s stock after selling 676 shares during the period. Channing Capital Management LLC’s holdings in Charles River Laboratories International were worth $9,217,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the business. Versant Capital Management Inc boosted its holdings in Charles River Laboratories International by 1,071.4% in the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 150 shares in the last quarter. Pinnacle Bancorp Inc. lifted its position in shares of Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after buying an additional 65 shares during the last quarter. Assetmark Inc. boosted its holdings in shares of Charles River Laboratories International by 1,153.3% in the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock valued at $37,000 after buying an additional 173 shares in the last quarter. Tortoise Investment Management LLC grew its position in shares of Charles River Laboratories International by 77.7% in the 4th quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company’s stock valued at $49,000 after buying an additional 115 shares during the last quarter. Finally, ORG Wealth Partners LLC acquired a new stake in Charles River Laboratories International during the 4th quarter worth $56,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Insider Activity at Charles River Laboratories International

In related news, CEO James C. Foster purchased 6,075 shares of the business’s stock in a transaction dated Thursday, February 20th. The stock was acquired at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the acquisition, the chief executive officer now directly owns 183,639 shares of the company’s stock, valued at $30,302,271.39. This trade represents a 3.42 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Joseph W. Laplume sold 4,400 shares of the business’s stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the sale, the executive vice president now directly owns 20,013 shares in the company, valued at approximately $3,252,112.50. This represents a 18.02 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.30% of the company’s stock.

Charles River Laboratories International Stock Down 0.4 %

Shares of NYSE:CRL opened at $175.13 on Tuesday. Charles River Laboratories International, Inc. has a fifty-two week low of $150.79 and a fifty-two week high of $274.77. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. The firm’s 50-day simple moving average is $168.99 and its 200-day simple moving average is $185.45. The company has a market cap of $8.96 billion, a price-to-earnings ratio of 1,167.55, a PEG ratio of 4.54 and a beta of 1.45.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating analysts’ consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company had revenue of $1 billion for the quarter, compared to analyst estimates of $983.63 million. During the same quarter in the previous year, the company earned $2.46 EPS. The firm’s revenue for the quarter was down 1.1% compared to the same quarter last year. As a group, equities research analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. The Goldman Sachs Group decreased their price objective on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating for the company in a research note on Thursday, January 23rd. CLSA downgraded Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price target on the stock. in a research note on Monday, November 18th. UBS Group reiterated a “neutral” rating and issued a $185.00 price objective (down previously from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. Bank of America decreased their price objective on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a report on Friday, December 13th. Finally, William Blair cut shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $198.36.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).